CELLECTIS S.A.

Company Overview

Cellectis S.A. is a clinical-stage biotechnological company that uses core proprietary technologies to develop products based on gene editing. Allogeneic Chimeric Antigen Receptor T-cells, or UCART, are product candidates for immunooncology therapeutic indications, while gene-edited hematopoietic stem and progenitor cells, or HSPC, are product candidates for other therapeutic indications. It has submitted approximately 54 additional patent application families related to CAR-T cell technology since 2012. Patent applications to produce allogeneic immune cells and CAR design are included in this portfolio.

Cellectis S.A. is developing several product candidates for the treatment of advanced hematologic malignancies. Universal CAR-T cells (UCARTs), the primary immuno-oncology product prospects, are allogeneic CAR-T cells designed for use as an “off-the-shelf” therapy. Every UCART product candidate is designed to target a specific antigen expressed on tumor cells and features unique engineering characteristics, including the ability to suppress alloreactivity and compatibility with specific treatment plans that cancer patients can follow.

Financial Highlights (FY 2025)

Company's Business Segments

• Collaboration Agreements : This segment of the company payments, services and royalties on licensed technologies and collaboration agreements.
• Licenses : This segment of the company is deriving revenue from third party companies for licensing them the Patents, Products developed by cellectis.
• Products and Services : This segment includes products like Allogeneic CAR-T Cell Pipeline for B-Cell Acute Lymphoblastic Leukemia (B-ALL), Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML).